TNF and inflammatory bowel disease: The advent of therapies targeting leukocyte trafficking (anti-integrins) or cytokines (anti-TNF, anti-IL-12/23) has transformed the management of IBD, significantly improving clinical remission and endoscopic healing while reducing disease-related morbidity (125).